A biophysical characterization of the peptide drug pramlintide (AC137) using empirical phase diagrams

Journal of Pharmaceutical Sciences

Volumn 97, Issue 7, 2008, Pages 2552-2567

  Nonoyama, Akihisa ^a   Laurence, Jennifer S ^a   Garriques, Liza ^b   Qi, Hong ^b   Le, Thao ^b   Middaugh, C Russell ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

Absorbance spectroscopy; Aggregation; Circular dichroism; Empirical phase diagram; Fluorescence spectroscopy; NMR; Peptide; Structural stability

Indexed keywords

PRAMLINTIDE;

ARTICLE; BIOPHYSICS; CIRCULAR DICHROISM; DRUG STABILITY; DRUG STRUCTURE; EMPIRICAL RESEARCH; FLUORESCENCE; NUCLEAR MAGNETIC RESONANCE; OPTICAL DENSITY; PH MEASUREMENT; TEMPERATURE SENSITIVITY; ULTRAVIOLET SPECTROSCOPY;

EID: 52449110979     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21197     Document Type: Article

References (37)

1. Lebovitz HE. 1984. Etiology and pathogenesis of diabetes mellitus. Pediatr Clin North Am 31:521-530.
2. Maedler K, Donath MY. 2004. b-Cells in type 2 diabetes: A loss of function and mass. Horm Res 62:67-73.
3. Baron AD, Kim D, Weyer C. 2002. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus. Curr Drug Targets Immune Endocr Metabol Disord 2:63-82.
4. Klein R, Klein BE, Moss SE, Cruickshanks KJ. 1996. The medical management of hyperglycemia over a 10-year period in people with diabetes. Diabetes Care 19:744-750.
5. Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, Reid KBM. 1987. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 84:8628-8632.
6. Young AA, Gedulin B, Vine W, Percy A, Rink TJ. 1995. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 38:642-648.
7. Scherbaum WA. 1998. The role of amylin in the physiology of glycemic control. Exp Clin Endocrinol Diabetes 106:97-102.
8. Lutz TA, Geary N, Szabady MM, Del Prete E, Scharrer E. 1995. Amylin decrease meal size in rats. Physiol Behav 58:1197-1202.
9. Day C. 2005. Amylin analogue as an antidiabetic agent. Br J Diabetes Vasc Dis 5:151-154.
10. Gerich JE. 1988. Role of insulin resistance in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus. Bailliere's Clin Endocrinol Metabolism 2:307-326.
11. Beaumont K, Kenney MA, Young AA, Rink TJ. 1993. High affinity amylin binding sites in rat brain. Mol Pharmacol 44:493-497.
12. Nishi M, Sanke T, Nagamatsu S, Bell GI, Steiner DF. 1990. Islet amyloid polypeptide. A new b cell secretory product related to islet amyloid deposits. J Biol Chem 265:4173-4176.
13. Clark A, Cooper GJ, Lewis CE, Morris JF, Willis AC, Reid KB, Turner RC. 1987. Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes. Lancet 2:231-234.
14. Kayed R, Bernhagen J, Greenfield N, Sweimeh K, Brunner H, Voelter W, Kapurniotu A. 1999. Conformational transitions of islet amyloid polypeptide (IAPP) in amyloid formation in vitro. J Mol Biol 287:781-796.
15. Westermark P, Engstroem U, Johnson KH, Westermark GT, Betsholtz C. 1990. Islet amyloid polypeptide: Pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci USA 87:5036-5040.
16. Goldsbury C, Goldie K, Pellaud J, Seelig J, Frey P, Muller SA, Kistler J, Cooper GJS, Aebi U. 2000. Amyloid fibril formation from full-length and fragments of amylin. J Struct Biol 130:352-362.
17. Leighton B, Cooper GJ. 1990. The role of amylin in the insulin resistance of non-insulin-dependent diabetes mellitus. Trends Biochem Sci 15:295-299.
18. Kajava AV, Aebi U, Steven AC. 2005. The parallel superpleated beta-structure as a model for amyloid fibrils of human amylin. J Mol Biol 348:247-252.
19. Cooper GJ, Day AJ, Willis AC, Roberts AN, Reid KB, Leighton B. 1989. Amylin and the amylin gene:Structure, function and relationship to islet amyloid and to diabetes mellitus. Biochim Bbiophys Aacta 1014:247-258.
20. Weyer C, Maggs DG, Young AA, Kolterman OG. 2001. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: A physiological approach toward improved metabolic control. Curr Pharm Des 7: 1353-1373.
21. Kruger DF, Gloster MA. 2004. Pramlintide for the treatment of insulin-requiring diabetes mellitus: Rationale and review of clinical data. Drugs 64: 1419-1432.
22. Fineman MS, Koda JE, Shen LZ, Strobel SA, Maggs DG, Weyer C, Kolterman OG. 2002. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism 51:636-641.
23. Ratner RE, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, Weyer C, Kolterman OG. 2002. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther 4:51-61.
24. Kleppinger EL, Vivian EM. 2003. Pramlintide for the treatment of diabetes mellitus. Ann Pharmacother 37:1082-1089.
25. Schmitz O, Brock B, Rungby J. 2004. Amylin agonists: A novel approach in the treatment of diabetes. Diabetes 53:S233-S238.
26. Ausar SF, Foubert TR, Hudson MH, Vedvick TS, Middaugh CR. 2006. Conformational stability and disassembly of Norwalk virus-like particles. Effect of pH and temperature. J Biol Chem 281:19478-19488.
27. Ausar SF, Rexroad J, Frolov VG, Look JL, Konar N, Middaugh CR. 2005. Analysis of the thermal and pH stability of human respiratory syncytial virus. Mol Pharm 2:491-499.
28. Fan H, Ralston J, Dibiase M, Faulkner E, Middaugh CR. 2005. Solution behavior of IFN-b-1a: An empirical phase diagram based approach. J Pharm Sci 94:1893-1911.
29. Jiang G, Joshi Sangeeta B, Peek Laura J, Brandau Duane T, Huang J, Ferriter Matthew S, Woodley Wendy D, Ford Brandi M, Mar Kevin D, Mikszta John A, Hwang CR, Ulrich R, Harvey Noel G, Middaugh CR, Sullivan Vincent J. 2006. Anthrax vaccine powder formulations for nasal mucosal delivery. J Pharm Sci 95:80-96.
30. Kueltzo LA, Ersoy B, Ralston JP, Middaugh CR. 2003. Derivative absorbance spectroscopy and protein phase diagrams as tools for comprehensive protein characterization: A bGCSF case study. J Pharm Sci 92:1805-1820.
31. Rexroad J, Evans Robert K, Middaugh CR. 2006. Effect of pH and ionic strength on the physical stability of adenovirus type 5. J Pharm Sci 95: 237-247.
32. Ruponen M, Braun CS, Middaugh CR. 2006. Biophysical characterization of polymeric and liposomal gene delivery systems using empirical phase diagrams. J Pharm Sci 95:2101-2114.
33. Lucas LH, Ersoy BA, Kueltzo LA, Joshi SB, Brandau DT, Thyagarajapuram N, Peek LJ, Middaugh CR. 2006. Probing protein structure and dynamics by second-derivative ultraviolet absorption analysis of cation-{pi} interactions. Protein Sci 15:2228-2243.
34. Kueltzo LA, Middaugh CR. 2003. Structural characterization of bovine granulocyte colony stimulating factor: Effect of temperature and pH. J Pharm Sci 92:1793-1804.
35. Neira JL, Sevilla P, Menendez M, Bruix M, Rico M. 1999. Hydrogen exchange in ribonuclease A and ribonuclease S: Evidence for residual structure in the unfolded state under native conditions. J Mol Biol 285:627-643.
36. Molday RS, Englander SW, Kallen RG. 1972. Primary structure effects on peptide group hydrogen exchange. Biochemistry 11:150-158.
37. Bai Y, Milne JS, Mayne L, Englander SW. 1993. Primary structure effects on peptide group hydrogen exchange. Proteins 17:75-86.